Safety and Efficacy of ALRV5XR in Men with Androgenetic Alopecia: A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial

The study evaluated the safety and efficacy of ALRV5XR, a treatment for androgenetic alopecia (AGA) in men, through a 24-week, double-blinded, placebo-controlled clinical trial with 46 participants. ALRV5XR significantly increased terminal hair density by 21 hairs/cm² and relative density by 16.4% compared to placebo, with all subjects in the treatment group responding positively. The treatment reversed hair miniaturization without adverse effects and demonstrated higher efficacy and response rates than standard therapies, suggesting its potential as a first-line treatment for hair regeneration in men with AGA. The study concluded that ALRV5XR could be a promising treatment for hair regrowth, with further research recommended to confirm these findings.